Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1989 Mar;96(3):661–669. doi: 10.1111/j.1476-5381.1989.tb11866.x

Effect of a new potent CCK antagonist, lorglumide, on caerulein- and bombesin-induced pancreatic secretion and growth in the rat.

C Scarpignato 1, G Varga 1, I Dobronyi 1, M Papp 1
PMCID: PMC1854413  PMID: 2470456

Abstract

1. The effect of lorglumide, a new potent cholecystokinin (CCK) antagonist, on pancreatic secretion and growth induced by caerulein and bombesin was studied in the rat. 2. Pancreatic exocrine secretion was studied both in vitro (isolated and perfused pancreatic segments) and in vivo (anaesthetized animals with cannulation of the common bile duct) whereas the trophic effect was investigated after short-term (5 days) administration of the peptides and/or lorglumide. 3. Both caerulein and bombesin stimulated amylase release from in vitro pancreatic segments in a concentration-dependent manner. Although the efficacy of both peptides was virtually identical, the potency of caerulein was higher than that of bombesin. Lorglumide displaced the concentration-response curves to caerulein to the right without affecting the maximum response, suggesting a competitive antagonism. The Schild plot analysis of data gave a straight line with a slope not significantly different from unity. The calculated pA2 for lorglumide was 7.31 +/- 0.45. The antagonist, however, was completely ineffective when tested against bombesin-induced amylase release. 4. In vivo experiments confirmed results from in vitro studies since lorglumide (5 and 10 mg kg-1) significantly reduced pancreatic exocrine secretion induced by caerulein without affecting the response to bombesin. 5. Administration of either peptide increased the weight of the pancreas, the total pancreatic protein and DNA, trypsin and amylase content. Lorglumide (10 mg kg-1), administered together with caerulein, reduced the peptide-induced increase in pancreatic weight, protein and enzyme content. On the contrary, when lorglumide was given together with bombesin, all the parameters that were examined were not altered by concomitant administration of the antagonist.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
661

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anastasi A., Erspamer V., Bucci M. Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia. 1971 Feb 15;27(2):166–167. doi: 10.1007/BF02145873. [DOI] [PubMed] [Google Scholar]
  3. BURTON K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J. 1956 Feb;62(2):315–323. doi: 10.1042/bj0620315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barthó L., Holzer P., Lembeck F., Lippe I. T., Setnikar I. Evaluation of a new and potent cholecystokinin antagonist on motor responses of the guinea-pig intestine. Br J Pharmacol. 1987 Apr;90(4):753–761. doi: 10.1111/j.1476-5381.1987.tb11229.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Basso N., Giri S., Improta G., Lezoche E., Melchiorri P., Percoco M., Speranza V. External pancreatic secretion after bombesin infusion in man. Gut. 1975 Dec;16(12):994–998. doi: 10.1136/gut.16.12.994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bertaccini G. Active polypeptides of nonmammalian origin. Pharmacol Rev. 1976 Jun;28(2):127–177. [PubMed] [Google Scholar]
  7. Bertaccini G., Coruzzi G. Evidence for and against heterogeneity in the histamine H2-receptor population. Pharmacology. 1981;23(1):1–13. doi: 10.1159/000137522. [DOI] [PubMed] [Google Scholar]
  8. Bommelaer G., Rozental G., Bernier C., Vaysse N., Ribet A. Action of secretagogues on amylase release from dog pancreatic acini. Digestion. 1981;21(5):248–254. doi: 10.1159/000198570. [DOI] [PubMed] [Google Scholar]
  9. Damgé C., Hajri A., Lhoste E., Aprahamian M. Comparative effect of chronic bombesin, gastrin-releasing peptide and caerulein on the rat pancreas. Regul Pept. 1988 Feb;20(2):141–150. doi: 10.1016/0167-0115(88)90047-x. [DOI] [PubMed] [Google Scholar]
  10. Erspamer V., Improta G., Melchiorri P., Sopranzi N. Evidence of cholecystokinin release by bombesin in the dog. Br J Pharmacol. 1974 Oct;52(2):227–232. doi: 10.1111/j.1476-5381.1974.tb09704.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ghatei M. A., George S. K., Major J. H., Carlei F., Polak J. M., Bloom S. R. Bombesin-like immunoreactivity in the pancreas of man and other mammalian species. Experientia. 1984 Aug 15;40(8):884–886. doi: 10.1007/BF01952009. [DOI] [PubMed] [Google Scholar]
  12. Ghatei M. A., Jung R. T., Stevenson J. C., Hillyard C. J., Adrian T. E., Lee Y. C., Christofides N. D., Sarson D. L., Mashiter K., MacIntyre I. Bombesin: action on gut hormones and calcium in man. J Clin Endocrinol Metab. 1982 May;54(5):980–985. doi: 10.1210/jcem-54-5-980. [DOI] [PubMed] [Google Scholar]
  13. HUMMEL B. C. A modified spectrophotometric determination of chymotrypsin, trypsin, and thrombin. Can J Biochem Physiol. 1959 Dec;37:1393–1399. [PubMed] [Google Scholar]
  14. Iwatsuki N., Petersen O. H. In vitro action of bombesin on amylase secretion, membrane potential, and membrane resistance in rat and mouse pancreatic acinar cells. A comparison with other secretagogues. J Clin Invest. 1978 Jan;61(1):41–46. doi: 10.1172/JCI108923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jankowski M., Gut W., Imbs D., Switalski L. Study of interaction between IgG and IgM antibodies against rubella virus by the immunofluorescence method. Acta Microbiol Pol. 1979;28(1):63–69. [PubMed] [Google Scholar]
  16. Jensen R. T., Jones S. W., Folkers K., Gardner J. D. A synthetic peptide that is a bombesin receptor antagonist. Nature. 1984 May 3;309(5963):61–63. doi: 10.1038/309061a0. [DOI] [PubMed] [Google Scholar]
  17. Jensen R. T., Zhou Z. C., Murphy R. B., Jones S. W., Setnikar I., Rovati L. A., Gardner J. D. Structural features of various proglumide-related cholecystokinin receptor antagonists. Am J Physiol. 1986 Dec;251(6 Pt 1):G839–G846. doi: 10.1152/ajpgi.1986.251.6.G839. [DOI] [PubMed] [Google Scholar]
  18. Knigge U., Holst J. J., Knuhtsen S., Petersen B., Krarup T., Holst-Pedersen J., Christiansen P. M. Gastrin-releasing peptide: pharmacokinetics and effects on gastro-entero-pancreatic hormones and gastric secretion in normal men. J Clin Endocrinol Metab. 1984 Aug;59(2):310–315. doi: 10.1210/jcem-59-2-310. [DOI] [PubMed] [Google Scholar]
  19. Konturek S. J., Król R., Tasler J. Effect of bombesin and related peptides on the release and action of intestinal hormones on pancreatic secretion. J Physiol. 1976 Jun;257(3):663–672. doi: 10.1113/jphysiol.1976.sp011390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  21. Lilja P., Greeley G. H., Jr, Thompson J. C. Pancreatic exocrine secretion. Release of gastrin and cholecystokinin in response to bombesin in pigs. Arch Surg. 1984 Jul;119(7):825–828. doi: 10.1001/archsurg.1984.01390190063014. [DOI] [PubMed] [Google Scholar]
  22. Makovec F., Chistè R., Bani M., Pacini M. A., Setnikar I., Rovati L. A. New glutaramic acid derivatives with potent competitive and specific cholecystokinin-antagonistic activity. Arzneimittelforschung. 1985;35(7):1048–1051. [PubMed] [Google Scholar]
  23. McDonald T. J., Houghton P., Challis J. R., Hramiak I. M. The effect of gastrin-releasing peptide on the endocrine pancreas. Ann N Y Acad Sci. 1988;547:242–254. doi: 10.1111/j.1749-6632.1988.tb23893.x. [DOI] [PubMed] [Google Scholar]
  24. Munro H. N., Fleck A. Recent developments in the measurement of nucleic acids in biological materials. A supplementary review. Analyst. 1966 Feb;91(79):78–88. doi: 10.1039/an9669100078. [DOI] [PubMed] [Google Scholar]
  25. Namba M., Ghatei M. A., Ghiglione M., Bloom S. R. Effects of decapeptide of mammalian bombesin and neuromedin B on pancreatic exocrine secretion in the rat. Digestion. 1986;34(2):105–114. doi: 10.1159/000199318. [DOI] [PubMed] [Google Scholar]
  26. Niederau C., Liddle R. A., Williams J. A., Grendell J. H. Pancreatic growth: interaction of exogenous cholecystokinin, a protease inhibitor, and a cholecystokinin receptor antagonist in mice. Gut. 1987;28 (Suppl):63–69. doi: 10.1136/gut.28.suppl.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Niederau C., Niederau M., Williams J. A., Grendell J. H. New proglumide-analogue CCK receptor antagonists: very potent and selective for peripheral tissues. Am J Physiol. 1986 Jun;250(6 Pt 1):G856–G860. doi: 10.1152/ajpgi.1986.250.6.G856. [DOI] [PubMed] [Google Scholar]
  28. Otsuki M., Fujii M., Nakamura T., Tani S., Oka T., Yajima H., Baba S. Effects of neuromedin B and neuromedin C on exocrine and endocrine rat pancreas. Am J Physiol. 1987 Apr;252(4 Pt 1):G491–G498. doi: 10.1152/ajpgi.1987.252.4.G491. [DOI] [PubMed] [Google Scholar]
  29. Pearson G. T., Singh J., Petersen O. H. Adrenergic nervous control of cAMP-mediated amylase secretion in the rat pancreas. Am J Physiol. 1984 May;246(5 Pt 1):G563–G573. doi: 10.1152/ajpgi.1984.246.5.G563. [DOI] [PubMed] [Google Scholar]
  30. Petersen H., Solomon T., Grossman M. I. Effect of chronic pentagastrin, cholecystokinin, and secretin on pancreas of rats. Am J Physiol. 1978 Mar;234(3):E286–E293. doi: 10.1152/ajpendo.1978.234.3.E286. [DOI] [PubMed] [Google Scholar]
  31. Rothman S. S., Wells H. Enhancement of pancreatic enzyme synthesis by pancreozymin. Am J Physiol. 1967 Jul;213(1):215–218. doi: 10.1152/ajplegacy.1967.213.1.215. [DOI] [PubMed] [Google Scholar]
  32. Silverman M. A., Greenberg R. E., Bank S. Cholecystokinin receptor antagonists: a review. Am J Gastroenterol. 1987 Aug;82(8):703–708. [PubMed] [Google Scholar]
  33. Solomon T. E., Petersen H., Elashoff J., Grossman M. I. Interaction of caerulein and secretin on pancreatic size and composition in rat. Am J Physiol. 1978 Dec;235(6):E714–E719. doi: 10.1152/ajpendo.1978.235.6.E714. [DOI] [PubMed] [Google Scholar]
  34. Susini C., Estival A., Scemama J. L., Ruellan C., Vaysse N., Clemente F., Esteve J. P., Fourmy D., Ribet A. Studies on human pancreatic acini: action of secretagogues on amylase release and cellular cyclic AMP accumulation. Pancreas. 1986;1(2):124–129. [PubMed] [Google Scholar]
  35. Tokiwa T., Uemura I., Murakami H., Tsuruoka S., Kaneko M. Studies on caerulein (FI6934). Absorption, distribution, metabolism and excretion of caerulein. Jpn J Pharmacol. 1975 Dec;25(6):747–762. doi: 10.1254/jjp.25.747. [DOI] [PubMed] [Google Scholar]
  36. Varga G., Papp M., Solomon T. E., Scarpignato C., Tóth I. E., Szabó D. Caerulein in supramaximal doses fails to stimulate pancreatic growth, but it forces secretory granulopoiesis. Acta Physiol Hung. 1988;71(1):99–106. [PubMed] [Google Scholar]
  37. Varga G., Scarpignato C., Papp M. Inhibition of pancreatic secretory and trophic response to caerulein by the H2-receptor antagonist ranitidine in the rat. Digestion. 1985;31(4):177–182. doi: 10.1159/000199196. [DOI] [PubMed] [Google Scholar]
  38. Walsh J. H., Wong H. C., Dockray G. J. Bombesin-like peptides in mammals. Fed Proc. 1979 Aug;38(9):2315–2319. [PubMed] [Google Scholar]
  39. Williams J. A., Bailey A., Steigerwalt R. W. Effects of proglumide on pancreatic acinar cell function. Digestion. 1983;27(4):227–233. doi: 10.1159/000198957. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES